Ran Nussbaum - 21 Oct 2022 Form 4/A - Amendment Insider Report for UroGen Pharma Ltd. (URGN)

Reporting relationship: Director
Issuer ticker: URGN
Reported as of: 21 Oct 2022
Net transaction value: +$285,114
SEC form: 4/A - Amendment
Accepted by SEC: 28 Feb 2023, 11:23:21 UTC
Original report date: 25 Oct 2022
Prior SEC filing: 28 Feb 2023
Next SEC filing: 30 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Jason D. Smith, Attorney-in-Fact

Key filing fact

Ran Nussbaum filed Form 4/A - Amendment for UroGen Pharma Ltd. (URGN) on 28 Feb 2023.

Key facts

This page summarizes Ran Nussbaum's Form 4/A - Amendment filing for UroGen Pharma Ltd. (URGN).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Feb 2023, 11:23.

Change

Previous filing in this sequence was filed on 28 Feb 2023.
Current net transaction value: +$285,114.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

URGN transaction

Ordinary Shares

Options Exercise

Transaction value: $285,114
Shares: +47,999
Change %: +3.3%
Price: $5.94
Shares after: 1,485,168
Date: 21 Oct 2022
Ownership: Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

URGN transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -32,723
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 21 Oct 2022
Ownership: By Pontifax (Israel) III Limited Partnership
Underlying class: Ordinary Shares
Underlying amount: 32,723
Exercise price: $5.94

URGN transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -15,276
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 21 Oct 2022
Ownership: By Pontifax Cayman III Limited Partnership
Underlying class: Ordinary Shares
Underlying amount: 15,276
Exercise price: $5.94

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On October 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,481,927 shares of securities beneficially owned following reported transaction instead of 1,485,168 shares.